Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 900 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Glucose Control Key in Reducing Cancer Risk for People with Type... December 7, 2021 Q&A: Learning About the Cancer Care Challenges LGBTQ+ People Face May 1, 2024 Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy July 20, 2018 Load more HOT NEWS “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer Cancer Research UK publishes gender and ethnicity pay gap reports
